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Abstract. The study demonstrated that endothelial dysfunction of bone microvasculature and 
deterioration of regional blood flow in bone developed eight weeks after ovariectomy in female 
white Wistar rats thus raising the risk of generalized osteoporosis. Nanoparticulated forms of 
losartan and resveratrol possessing endothelioprotective action effectively prevented reduction of 
regional microcirculation in bone tissue through keeping it at the same level as intact rats had. It 
allowed maintaining an adequate level of bone remodeling processes which was manifested in 
slowing of thinning of bone trabeculas and in prevention of possible microfractures in them. 
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Osteoporosis (OP) is a systemic skeletal disease 
characterized by reduction of a bone mass in a unit 
volume and deterioration of the bone tissue 
microarchitectonics which results in increased bone 
brittleness and high risk of bone fracture. The main 
reason for OP development involves unbalance 
between two basic processes of bone remodeling, i.e. 
osteogenesis and osteoresorption [1]. 
Deterioration of bone vascular supply [10] 
causing osteoblasts activity inhibition as well as 
osteoclasts activation is one of significant stages in 
pathogenic mechanism of OP. Thus during the earlier 
investigations we’ve managed to establish close 
interrelation between sufficient bone tissue vascular 
supply and bone tissue quality which is evaluated 
though the thickness of bone trabeculas  and bone 
tissue resistance to external influence [8]. 
As is known the structure of bone tissue 
microvasculature has essential differences as compared 
to the morphology of vasculature of the other body 
tissues. The bone microcirculatory vessel has only 
endothelium which mediates the whole humoral 
regulation of exchange between bone cells and blood. In 
the course of the earlier investigations carried out by us 
it was demonstrated that generalized hypoestrogenism-
induced OP in female Wistar rats was accompanied by 
the signs of endothelial dysfunction (ED) development 
which might cause deterioration of regional vascular 
supply and might result in derangement of osteogenesis 
and osteoreparation processes and induce development 
of OP.  
The current nosotropic therapy does not pay 
sufficient attention to the medicines with 
endothelioprotective properties and therefore having 
positive effect on bone tissue vascular supply. This is 
indicative of importance of studying osteoprotective 
action of medicines with proved positive 
endotheliotropic effects such as for example losartan 
and resveratrol. At the same time increase of 
efficiency and reduction of the number of adverse 
effects caused by a medicine is an urgent problem of 
the current experimental and clinical pharmacology, 
such purpose may be reached by a medicine 
nanoparticulation along with its dose reduction. Due 
to the above the present investigation is aimed at 
study of the anti-osteoporosis properties of 
nanoparticulated resveratrol and losartan. 
The research techniques 
The experiments involved 267 white Wistar 
female rats with the weight of 250±25 g. Systemic 
OP simulation was accomplished through 
intraperitoneal anesthesia with chloral hydrate 
solution in the dose of 300 mg/kg after which 
bilateral ovariectomy was performed [5]. Progression 
of generalized OP was evaluated eight weeks (on the 
57
th
 day) after the surgery. 
The level of microcirculation was assessed in the 
tissues of proximal metaphysis of the femoral bone. For 
this purpose an animal was fixed on a surgical table [7] 
and a monocortical orifice was bored in the femoris 
after which a conductor shaft [6] was introduced in the 
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orifice in order to hold stably a sensor used for bone 
microcirculation measuring. The following equipment 
of Biopac Systems Company was used for obtaining 
microcirculation data: polygraphs MP100 and MP150 
with a laser Doppler flowmetry (LDF) module 
LDF100C and a sensor TSD144. The LDF result 
recording was made via the program AcqKnowledge of 
3.8.–4.2. versions, microcirculation value was 
expressed in perfusion units (PU). 
Progression of hypoestrogenism-induced ED 
was assessed after measuring an intraosteal 
microcirculation level which was made trough a test 
for endothelium-dependent vasodilation (EDVD) as a 
reaction to bolus intravenous administration of acetyl 
choline solution in the dose of 40 µg/kg [16] and for 
endothelium-independent vasodilation (EIVD) as a 
reaction to bolus administration of sodium 
nitroprusside solution in the dose of 30 µg/kg [2]. In 
order to provide objective estimation of endothelial 
dysfunction in case of generalized OP an endothelial 
dysfunction coefficient (EDC) was calculated based 
on LDF data in the bone [4, 8]. 
Morphological examination of the femoral bone 
proximal metaphysis was made within an integral 
assessment of efficiency of both the studied 
medicines alone and their combinations in order to 
confirm OP progression. Slide plates with tissue 
specimens were analyzed by optical microscopy and 
photos of the bone trabeculas were taken by means of 
matching a camera lens and a microscope eyepiece. 
For the purposes of bone tissue histomorphometry the 
precalibrated program ImageJ of 1.39–1.43 version 
was used, with the aid of the mentioned program the 
bone trabeculas width was measured and expressed in 
millimeters.  
We’ve chosen nanoparticulated forms of the 
medicine having endothelioprotective and 
osteoprotective effect as proved by the previous 
investigations, namely losartan potassium and 
resveratrol for investigation of anti-osteoporosis 
action [9]. In the course of experiments losartan (in 
the dose of 6 mg/kg) as well as its nanoparticulated 
form (hereafter «n-losartan», in the dose of 0.6 
mg/kg) were administered intragastrically every day 
once a day over a period of eight weeks after 
osteoporosis simulation. Resveratrol (in the dose of 2 
mg/kg) as well as its nanoparticulated form (hereafter 
«n-resveratrol», in the dose of 0.2 mg/kg) was 
introduced intraperitoneally according to the same 
regimen. Bivalos in the dose of 171 mg/kg was used 
as a reference substance. 
A group of controls was represented by the 
group of animals with experimental OP but not 
receiving pharmacological correction. A group of 
intact rats included animals which were subjected to 
false surgery (false ovariectomy not involving 
ectomy of ovaries). 
Statistical analysis of the obtained data was 
made in the Microsoft Excel program. «Descriptive 
statistics» was used for calculation of the mean value 
(M) and the standard error (m). «Two-sample t-test 
with different variances» was used for comparison of 
indices in the different groups of animals and 
determination of significance of differences between 
them. The differences having p<0.05 value were 
considered as statistically significant. 
The research results 
The LDF results allowed to ascertain 
significantly lower level of microcirculation in the 
bone tissue of the rats eight weeks after ovariectomy 
(61.52±3.74 PU; n=42) as compared to the intact 
animals (100.51±4.41 PU; n=30). 
Microcirculation intensity reduction with the 
following blood flow indexes recovery was observed 
in response to systemic administration of acetyl 
choline and nitroprusside. For example 
microcirculation level decrease during EDVD tests in 
the group of intact animals amounted to 46.7±3.8% 
of the initial indices on the average, in the group of 
rats with experimental OP this index amounted to 
38.9±3.8%. When EIVD reaction was checked the 
level of microcirculation in the group with intact rats 
reduced by 29.0±3.5% on the average as compared to 
the initial value and in the group of controls by 
27.3±5.3%. 
EDC in the group of intact animals constituted 
1.3±0.2 and in the group with experimental OP EDC 
was significantly higher and made 2.4±0.2. 
Osteoporosis-related changes in the skeletal 
bones were histologically proven for all of the rats 
eight weeks after ovariectomy, i.e. there was 
observed thinning of the bone trabeculas and 
extension of intertrabecular spaces. Besides some 
histological specimens demonstrated microfractures 
of the bone trabeculas. Statistically significant 
decrease of the average bone trabeculas width within 
the studied location was an objective criterion of OP 
progression eight weeks after the bilateral 
ovariectomy. Thus the average bone trabeculas width 
in the proximal femoral metaphysic in the rats with 
experimental OP (61.68±1.24 µm) was lower than 
that of the intact animals (97.69±1.02 µm) by 36.8%. 
In the course of analysis of the studied medicines it 
was found out that losartan (n=35), resveratrol (n=20) 
and their nanoparticulated forms (n=20) as well as 
Bivalos reference substance (n=20) effectively 
prevented reduction of the level of regional blood flow 
in the femoral bony tissue (Fig. 1).
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Figure 1. Results of the effect of the studied medicines on bone tissue blood supply 8 weeks after bilateral ovariectomy. 
Note. Hereinafter: * – p<0.05 as compared to the group of intact animals; ** – p<0.05 as compared to the group of rats with 
osteoporosis 
The results of LDF in the groups of rats 
receiving bivalos, losartan, n-losartan, resveratrol and 
n-resveratrol approximated the indexes of the intact 
animals and had no statistical differences between 
each other as well as had statistically higher values 
than that in the group of controls.  
It was found out that all of the studied medicines 
except for bivalos made the ratios between the areas 
of triangles above the curves characterizing recovery 
of the level of bone microcirculation due to 
administration of nitroprusside and acetyl choline 
equal to the same ratios of the intact animals. Hence 
the studied medicines induced statistically significant 
reduction of EDC to the following levels: losartan – 
1.5±0.2, n-losartan – 1.5±0.2, resveratrol – 1.3±0.2, 
n-resveratrol – 1.3±0.1, thus demonstrating 
endothelioprotective action. The value of EDC in the 
group of animals receiving bivalos made 2.1±0.2. 
Optical microscopy of the femoral bone cuts of the 
rats receiving medicines demonstrated preservation of 
the bone tissue structure and bigger width of bone 
trabeculas as compared to the rats having OP and not 
receiving drugs. It has been found that bivalos, losartan, 
n-losartan, resveratrol and n-resveratrol prevented 
reduction of the average bone trabeculas width to the 
level which the animals with experimental OP had 
however the average trabeculas width didn’t reach the 
values characteristic for intact rats (Fig. 2).
Figure 2. The results of the impact of medicines on the width of bone trabeculas 
In the course of study of activity of 
combinations of the investigated medicines it has 
been found that the combinations of losartan in the 
dose of 6 mg/kg with resveratrol in the dose of 2 
mg/kg (n=20), n-losartan in the dose of 0.6 mg/kg 
with resveratrol in the dose of 2 mg/kg (n=20), 
losartan in the dose of 6 mg/kg with n-resveratrol in 
the dose of 0.2 mg/kg (n=20) and n-losartan in the 
dose of 0.6 mg/kg with n-resveratrol in the dose of 
0.2 mg/kg (n=20) more effectively prevented 
lowering of the level of regional blood circulation in 
the femoral bone tissue as against monotherapy with 
the stated medicines  (Fig. 3). 
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Figure 3. The results of the effect of combinations of medicines on the blood supply of the bone tissue 
The results of LDF in the groups of rats 
receiving combined therapy had no statistical 
differences as compared to the indices of the intact 
animals and often even exceeded the same, had no 
statistical differences between each other and 
significantly exceeded both the values characteristic 
for the group of controls and the group of animals 
receiving bivalos. 
It has been found that all of the studied drug 
combinations made the ratios between the areas of 
triangles above the curves characterizing recovery of 
the level of bone microcirculation due to administration 
of nitroprusside and acetyl choline equal to the same 
ratios of the intact animals. Hence the studied drug 
combinations induced statistically significant reduction 
of EDC to the following levels: losartan + resveratrol – 
1.1±0.1, n-losartan + resveratrol – 1.2±0.1, losartan + n-
resveratrol – 1.4±0.2, n-losartan + n-resveratrol – 
1.2±0.1 thus demonstrating pronounced 
endothelioprotective action. 
Optical microscopy of the femoral bone cuts of the 
rats receiving treatment by the studied drug 
combinations demonstrated preservation of the bone 
tissue structure and bigger width of bone trabeculas as 
compared to the rats having OP and not receiving 
medicines. It has been found that the combinations of 
the investigated medicines efficiently prevented 
reduction of average bone trabeculas width to the level 
which the animals with experimental OP had (Fig. 4).  
 
 
 
Figure 4. The results of the effect of combinations of drugs on the width of bone trabeculas 
Discussion 
Development of fully functional 
microcirculatory bloodstream and systematic 
condition of regional microcirculation in bone tissue 
have utmost value for maintenance of bone 
homeostasis. Impairment of bone tissue blood supply 
may induce occurrence of such pathologies of 
musculoskeletal system as osteonecrosis [12], 
osteomyelitis [17] or osteoporosis [11, 18]. 
Endothelium in mature vasculature plays the major 
regulatory role ensuring connection between other 
layers in a vascular wall and giving adequate 
response to their needs by means of secretion of 
mediators [3]. Therefore in our opinion endothelium 
of bone tissue vasculature being an essential part of a 
bone determines the state of regional 
microcirculation to a large extent hence it is 
responsible for maintaining homeostasis in a bone.  
The above statement is approved by the works 
of a number of authors who declare for example that 
VEGF (a key regulator of a cascade of events 
resulting in vascular system formation and 
development) plays a significant role in the processes 
of remodeling [13] and repair of bone tissue injuries 
[14]. Thus it was demonstrated that inhibition of 
VEGF induced increase of the width of the femoral 
and tibial growth plates, reduction of angiogenesis 
intensity in the growth plates, disappearance of blood 
vessels in the metaphysial growth plate as well as 
decrease in intensity of formation of a bone 
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trabecular structure [13] and intensification of spongy 
bone tissue resorption [15]. 
At the present time the medicines having 
endothelioprotective properties are being actively 
studied as well as possible pathoegenetic mechanisms 
of their effect on vascular endothelium are being 
formulated. 
Endothelioprotective influence of angiotensin 
receptor antagonists is obviously realized through 
AT1-receptors block which results in decrease of 
superoxide radicals production, reduction of NO 
bonding degree and its accumulation. Since AT1-
receptors stimulation favors formation of superoxides 
which inactivate NO and stimulation of AT2-
receptors results in vasodilation and intensification of 
natriuresis due to activation of the system of 
bradykinin, NO and cyclic guanosine monophosphate 
the effect of АТ-2 (intensification of synthesis or 
inactivation of NO) depends on the type of receptors 
which have prevalent interaction with AT-2. 
Therefore it’s obvious that with AT1-receptors block 
there exist favorable conditions for intensified 
functioning of free AT2-receptors which results in 
accumulation of NO. 
Resveratrol as a representative of the group of 
phytoalexins induces endothelium-dependent 
relaxation of vasculature through intensification of 
nitric oxide production and the following growth of 
the level of cyclic guanosine monophosphate. At the 
same time the mentioned effects are diminished in 
case of administration of competitive inhibitors of 
NO-synthase, i.e. N
G
- monomethyl-L-arginine and 
N
G
-nitro-L- arginine. It is known that short-time 
effect of resveratrol in low concentrations (1-10 µM) 
on endotheliocytes results in increase of the quantity 
of the produced nitric oxide which can be explained 
by short-term intensification of eNOS and reduction 
of superoxide production in endothelium. Resveratrol 
promotes eNOS expression and VEGF in 
chronological order. On the other hand inhibition of 
NO production by eNOS inhibitors results in 
significant reduction of mitogenic and angiogenic 
effects stimulated by VEGF.  
Use of nanoparticulated forms of losartan and 
resveratrol in the present study allowed achieving 
two-fold reduction of the doses of the tested 
medicines with maintenance of comparable 
therapeutic outcome. In addition the nanoparticulated 
forms of losartan and resveratrol demonstrated 
efficient osteoprotective action both for monotherapy 
and for combination of drugs.  
Therefore the nanoparticulated forms of losartan 
(AT1-receptors blocker)  and resveratrol (a 
representative of the group of phytoalexins) through 
their endothelioprtective effect on endothelium of 
microcirculatory bloodstream of bone tissue 
efficiently prevent decrease of intensity of regional 
blood supply in bone tissue in case of experimental 
osteoporosis and have osteoprotective action 
consisting in positive influence of such medicines on 
the processes of bone remodeling and restoration.    
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